Skip to main content
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1974 Apr;37(4):427–430. doi: 10.1136/jnnp.37.4.427

Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias1

Harold L Klawans Jr 1,2,2, William J Weiner 1,2
PMCID: PMC494674  PMID: 4838914

Abstract

Haloperidol was used in 12 patients in an attempt to improve l-dopa induced dyskinesias. In eight patients any improvement in dyskinesias was associated with increased Parkinsonism. In four patients the dyskinesias initially improved without clinical deterioration. Within several weeks, however, the disability due to Parkinsonism increased in these four patients as well. These observations suggest that long term haloperidol does not effectively decrease l-dopa induced dyskinesias without worsening Parkinsonism.

Full text

PDF
427

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbeau A. L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. Can Med Assoc J. 1969 Dec 27;101(13):59–68. [PMC free article] [PubMed] [Google Scholar]
  2. Birkmayer W. Der alpha-Methyl-P-Tyrosin-Effekt bei extrapyramidalen Erkrankungen. Wien Klin Wochenschr. 1969 Jan 3;81(1):10–12. [PubMed] [Google Scholar]
  3. CANTER G. J., DE LA TORRE R., MIER M. A method for evaluating disability in patients with Parkinson's disease. J Nerv Ment Dis. 1961 Aug;133:143–147. doi: 10.1097/00005053-196108000-00010. [DOI] [PubMed] [Google Scholar]
  4. Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969 Feb 13;280(7):337–345. doi: 10.1056/NEJM196902132800701. [DOI] [PubMed] [Google Scholar]
  5. Cotzias G. C., Van Woert M. H., Schiffer L. M. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967 Feb 16;276(7):374–379. doi: 10.1056/NEJM196702162760703. [DOI] [PubMed] [Google Scholar]
  6. Godwin-Austen R. B., Tomlinson E. B., Frears C. C., Kok H. W. Effects of L-dopa in Parkinson's disease. Lancet. 1969 Jul 26;2(7613):165–168. doi: 10.1016/s0140-6736(69)91417-2. [DOI] [PubMed] [Google Scholar]
  7. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  8. Jameson H. D. Pyridoxine for levodopa-induced dystonia. JAMA. 1970 Mar 9;211(10):1700–1700. [PubMed] [Google Scholar]
  9. Klawans H. L., Jr A pharmacologic analysis of Huntington's chorea. Eur Neurol. 1970;4(3):148–163. doi: 10.1159/000114017. [DOI] [PubMed] [Google Scholar]
  10. Klawans H. L., Jr, Garvin J. S. Treatment of parkinsonism with L-dopa (study of 105 patients). Dis Nerv Syst. 1969 Nov;30(11):737–746. [PubMed] [Google Scholar]
  11. Klawans H. L., Jr, Ilahi M. M., Ringel S. P. Toward an understanding of the pathophysiology of Huntington's chorea. Confin Neurol. 1971;33(5):297–303. doi: 10.1159/000103145. [DOI] [PubMed] [Google Scholar]
  12. Man P. L. Long-term effects of haloperidol. Dis Nerv Syst. 1973 Feb;34(2):113–118. [PubMed] [Google Scholar]
  13. McLennan H., York D. H. The action of dopamine on neurones of the caudate nucleus. J Physiol. 1967 Apr;189(3):393–402. doi: 10.1113/jphysiol.1967.sp008175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Postma J. U. Haloperidol in dopa-induced choreo-athetosis. Psychiatr Neurol Neurochir. 1972 Jan-Feb;75(1):69–71. [PubMed] [Google Scholar]
  15. Yahr M. D., Duvoisin R. C., Schear M. J., Barrett R. E., Hoehn M. M. Treatment of parkinsonism with levodopa. Arch Neurol. 1969 Oct;21(4):343–354. doi: 10.1001/archneur.1969.00480160015001. [DOI] [PubMed] [Google Scholar]
  16. York D. H. Possible dopaminergic pathway from substantia nigra to putamen. Brain Res. 1970 Jun 3;20(2):233–249. doi: 10.1016/0006-8993(70)90291-x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES